Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inventiva S.A. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IVA
Nasdaq
2830
inventivapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inventiva S.A.
Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside
- Jun 30th, 2026 10:34 am
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
- Jun 29th, 2026 7:35 am
Claret Capital Partners participates in €130m financing for Inventiva
- Jun 16th, 2026 3:12 am
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
- Jun 16th, 2026 2:52 am
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
- Jun 12th, 2026 2:00 pm
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
- Jun 11th, 2026 7:35 am
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
- Jun 9th, 2026 2:00 pm
Statement of Total Voting Rights and Shares Forming The Company’s Share Capital as of May 22, 2026
- Jun 9th, 2026 2:00 pm
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
- Jun 2nd, 2026 6:30 am
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
- Jun 2nd, 2026 6:29 am
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
- Jun 1st, 2026 11:30 pm
Inventiva Reports 2026 First Quarter Financial Information¹
- May 26th, 2026 2:00 pm
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
- May 21st, 2026 2:00 pm
Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses
- May 21st, 2026 12:11 am
How The Inventiva (ENXTPA:IVA) Story Is Shifting As Analyst Views Grow More Divided
- May 19th, 2026 6:21 pm
Inventiva to Present Abstracts at the EASL Congress 2026
- May 13th, 2026 12:30 am
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
- Apr 22nd, 2026 4:03 pm
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
- Apr 22nd, 2026 2:00 pm
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
- Apr 8th, 2026 2:00 pm
How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions
- Apr 6th, 2026 10:32 pm
Scroll